Cargando…

Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket

We report computer-aided design of new lactone–chalcone and isatin–chalcone (HLCIC) inhibitors of the falcipain-2 (PfFP-2). 3D models of 15 FP-2:HLCIC1-15 complexes with known observed activity (IC (50) (exp)) were prepared to establish a quantitative structure–activity (QSAR) model and linear corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Allangba, Koffi N’Guessan Placide Gabin, Keita, Mélalie, Kre N’Guessan, Raymond, Megnassan, Eugene, Frecer, Vladimir, Miertus, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352947/
https://www.ncbi.nlm.nih.gov/pubmed/30696325
http://dx.doi.org/10.1080/14756366.2018.1564288
_version_ 1783390946803580928
author Allangba, Koffi N’Guessan Placide Gabin
Keita, Mélalie
Kre N’Guessan, Raymond
Megnassan, Eugene
Frecer, Vladimir
Miertus, Stanislav
author_facet Allangba, Koffi N’Guessan Placide Gabin
Keita, Mélalie
Kre N’Guessan, Raymond
Megnassan, Eugene
Frecer, Vladimir
Miertus, Stanislav
author_sort Allangba, Koffi N’Guessan Placide Gabin
collection PubMed
description We report computer-aided design of new lactone–chalcone and isatin–chalcone (HLCIC) inhibitors of the falcipain-2 (PfFP-2). 3D models of 15 FP-2:HLCIC1-15 complexes with known observed activity (IC (50) (exp)) were prepared to establish a quantitative structure–activity (QSAR) model and linear correlation between relative Gibbs free energy of enzyme:inhibitor complex formation (ΔΔG (com)) and IC (50) (exp): pIC (50) (exp) = −0.0236 × ΔΔG (com)+5.082(#); R (2) = 0.93. A 3D pharmacophore model (PH4) derived from the QSAR directed our effort to design novel HLCIC analogues. During the design, an initial virtual library of 2621440 HLCIC was focused down to 18288 drug-like compounds and finally, PH4 screened to identify 81 promising compounds. Thirty-three others were added from an intuitive substitution approach intended to fill better the enzyme S2 pocket. One hundred and fourteen theoretical IC(50) (IC (50) (pre)) values were predicted by means of (#) and their pharmacokinetics (ADME) profiles. More than 30 putative HLCICs display IC (50) (pre) 100 times superior to that of the published most active training set inhibitor HLCIC1.
format Online
Article
Text
id pubmed-6352947
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-63529472019-02-06 Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket Allangba, Koffi N’Guessan Placide Gabin Keita, Mélalie Kre N’Guessan, Raymond Megnassan, Eugene Frecer, Vladimir Miertus, Stanislav J Enzyme Inhib Med Chem Research Paper We report computer-aided design of new lactone–chalcone and isatin–chalcone (HLCIC) inhibitors of the falcipain-2 (PfFP-2). 3D models of 15 FP-2:HLCIC1-15 complexes with known observed activity (IC (50) (exp)) were prepared to establish a quantitative structure–activity (QSAR) model and linear correlation between relative Gibbs free energy of enzyme:inhibitor complex formation (ΔΔG (com)) and IC (50) (exp): pIC (50) (exp) = −0.0236 × ΔΔG (com)+5.082(#); R (2) = 0.93. A 3D pharmacophore model (PH4) derived from the QSAR directed our effort to design novel HLCIC analogues. During the design, an initial virtual library of 2621440 HLCIC was focused down to 18288 drug-like compounds and finally, PH4 screened to identify 81 promising compounds. Thirty-three others were added from an intuitive substitution approach intended to fill better the enzyme S2 pocket. One hundred and fourteen theoretical IC(50) (IC (50) (pre)) values were predicted by means of (#) and their pharmacokinetics (ADME) profiles. More than 30 putative HLCICs display IC (50) (pre) 100 times superior to that of the published most active training set inhibitor HLCIC1. Taylor & Francis 2019-01-30 /pmc/articles/PMC6352947/ /pubmed/30696325 http://dx.doi.org/10.1080/14756366.2018.1564288 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Allangba, Koffi N’Guessan Placide Gabin
Keita, Mélalie
Kre N’Guessan, Raymond
Megnassan, Eugene
Frecer, Vladimir
Miertus, Stanislav
Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title_full Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title_fullStr Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title_full_unstemmed Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title_short Virtual design of novel Plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the S2 active site pocket
title_sort virtual design of novel plasmodium falciparum cysteine protease falcipain-2 hybrid lactone–chalcone and isatin–chalcone inhibitors probing the s2 active site pocket
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352947/
https://www.ncbi.nlm.nih.gov/pubmed/30696325
http://dx.doi.org/10.1080/14756366.2018.1564288
work_keys_str_mv AT allangbakoffinguessanplacidegabin virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket
AT keitamelalie virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket
AT krenguessanraymond virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket
AT megnassaneugene virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket
AT frecervladimir virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket
AT miertusstanislav virtualdesignofnovelplasmodiumfalciparumcysteineproteasefalcipain2hybridlactonechalconeandisatinchalconeinhibitorsprobingthes2activesitepocket